Navigation Links
Gen-Probe Reports Financial Results for the Fourth Quarter of 2011
Date:2/14/2012

expense):Investment and interest income

8,695

8,69511,765

11,765Interest expense

(2,070)

(2,070)(2,216)

(2,216)Gain on contingent consideration

——

7,994

7,994Other-than-temporary impairment loss on equity investment

(39,482)

(39,482)—

—Other income (expense), net

(236)

(236)(177)

(177)Total other income (expense), net

6,389

(39,482)

(33,093)9,372

7,994

17,366Income before income tax

162,245

(69,088)

93,157158,753

(3,542)

155,211Income tax expense

49,226

(6,193)

43,03351,303

(3,029)

48,274Net income

$113,019

$  (62,895)

$  50,124$107,450

$  (513)

$106,937Net income per share:Basic

$  2.39

$  (1.33)

$  1.06$  2.21

$  (0.01)

$  2.20Diluted

$  2.34

$  (1.30)

$  1.04$  2.19

$  (0.01)

$  2.18Weighted average shares outstanding:Basic

47,25447,25448,56048,560Diluted

48,38748,38749,03349,033Gen-Probe IncorporatedConsolidated Statements of Cash Flows - GAAP(In thousands)

(Unaudited)Twelve Months EndedDecember 31,20112010Operating activities:Net income

$  50,124$  106,937Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization

46,56944,529Amortization of premiums on investments, net of accretion of discounts

9,5929,573Stock-based compensation

24,74124,075Excess tax benefit from employee stock-based compensation

(5,080)(3,692)Deferred revenue

850(1,808)Deferred income tax

(4,220)(3,745)Other
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Gen-Probe Reports Financial Results for the Second Quarter of 2011
2. Gen-Probe to Webcast Two Upcoming Investor Presentations
3. Gen-Probe Announces Webcast of First Quarter 2011 Earnings Conference Call
4. Gen-Probe Reports Financial Results for the Fourth Quarter and Full Year 2010
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2010 Earnings Conference Call
6. Gen-Probe to Webcast Presentation at the 29th Annual J.P. Morgan Healthcare Conference
7. Gen-Probe Acquires GTI Diagnostics for $53 Million in Cash
8. Gen-Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts
9. Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments
10. Gen-Probe to Consolidate Industrial Assets Into New, Independent Company
11. Gen-Probe to Webcast Four Upcoming Investor Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... cell phones to cars and flashlights, batteries play ... technology companies constantly are seeking ways to improve ... time using a water-based solution, researchers at the ... more efficient nuclear battery that could be used ... source in automobiles and also in complicated applications ...
(Date:9/16/2014)... 16, 2014 BlueInGreen® , ... efficient method for delivering dissolved gases into liquids, ... as a manufacturer’s representative firm to its ... products for municipal water and wastewater applications in ... H2Flow was founded in 1992 and serves Quebec ...
(Date:9/16/2014)... Sept. 16, 2014  Donald Fresne, President and CEO of ... Stephan Vagner , PhD to its Scientific Advisory Committee. ... Toulouse, France , performed research at Embl (European ... at Inserm, the French institute of health and medical research. ... at the Curie Institute, Orsay, France , ...
(Date:9/16/2014)... 16, 2014  The Council for Entrepreneurial Development ... in the country, today released a mid-year update ... It showed that in the first ... startups in the technology, life science, advanced ... from a variety of sources. Significant investment in technology ...
Breaking Biology Technology:BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4
... Annual Revenues Up, Net Loss Down, Cash Position Strong, as Pipeline ... ... (Nasdaq: EXEL ) today reported financial results for the full,year and ... $113.5 million, compared to $98.7 million in,2006. The increase in revenues for ...
... PALO ALTO, Calif., Feb. 14 Telik, Inc.,(Nasdaq: ... webcast will,be held on Thursday, February 21, 2008 at ... release earlier that day of the company,s,financial results for ... The conference call will be accessible via Telik,s ...
... Executives from Senexis,and O2H, both located in Cambridge, ... synthetic and computational chemistry services to the drug,discovery ... "We believe our collaboration with O2H leverages the ... search for new,therapeutics to treat ageing-related diseases by ...
Cached Biology Technology:Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration 2
(Date:9/16/2014)... Sept. 16, 2014  Valencell, Inc., a leader in ... one of 18 "Showcase Companies" representing North ... annual CED Tech Venture Conference on September 16-17 th ... Center in Raleigh, North Carolina . ... a discussion during the "Digital Health Spotlight Sector" on ...
(Date:9/15/2014)... digestion to disease resistance. Despite the fact that tropical ... planet, more is known about belly-button bacteria than bacteria ... working on Panama,s Barro Colorado Island discovered that small ... more than 400 different kinds of bacteria. The combined ... different kinds. , Bacteria in tropical forests may also ...
(Date:9/15/2014)... a common epilepsy drug to a morphine regimen can ... Moreover, the combination can reduce the dosage of the ... of pain researchers at Indiana University. , The result ... pain, a difficult-to-treat condition often felt in the arms ... "There is a huge unmet need for better treatments ...
Breaking Biology News(10 mins):Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
... ago, the German Physical Society (DPG) has introduced the ... interdisciplinary applications of physics. The Prize, endowed with 5000 ... instrument to encourage research in this direction. This ... Max Planck Institute for Evolutionary Biology in Pln. He ...
... , New Rochelle, NY -- A novel method for ... help advance research on tissue engineering and regeneration, as ... Part C, Methods, a peer-reviewed journal from Mary Ann ... free online at the Tissue Engineering website ...
... proteins that actively pump a wealth of molecules across ... functions in humans. Genetic defects in ABC transporters can ... cystic fibrosis, and certain ABC transporters also cause resistance ... increased amounts of ABC transporters that pump chemotherapeutic substances ...
Cached Biology News:'Young Scientist Award for Socio- and Econophysics 2012' for Arne Traulsen 2
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Bethyl Laboratories Epitope Retrieval Buffer-Reduced pH will unmask antigenic sites from formaldehyde fixation and allow for subsequent immunostaining. Shelf-Life: 1 year from date of receipt...
Mycoplasma and virus tested...
Mycoplasma and virus tested...
Biology Products: